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Abstract
Background: Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based
therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged
ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex
regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally
manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason,
a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has
been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden
our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC
(LG-MSCs) population.
Methods: Human LG samples and their LG-MSCs were analyzed by immunohistochemistry for pericyte, endothelial
and mesenchymal stromal cell marker expression. Angiogenesis was investigated testing the conditioned media (CM)
of LG (LG-CM) and LG-MSCs (LG-MSCs-CM) on cultured endothelial cells (HUVECs), evaluating proliferation, cord
formation, and the expression of the adhesion molecules (AM) VCAM-1 and ICAM-1. The macrophage cell line
U937 was used to evaluate the anti-inflammatory properties, such as migration, adhesion on HUVECs, and release
of RANTES and MCP-1.
Results: Our results indicate that LG contained a very high number of mesenchymal cells expressing NG2 and
CD146 (both pericyte markers) together with an abundant microvascular endothelial cell (mEC) population.
Substantially, both LG-CM and LG-MSC-CM increased cord formation, inhibited endothelial ICAM-1 and VCAM-1
expression following TNFα stimulation, and slightly improved HUVEC proliferation. The addition of LG-CM and
LG-MSC-CM strongly inhibited U937 migration upon stimulation with the chemokine MCP-1, reduced their adhesion
on HUVECs and significantly suppressed the release of RANTES and MCP-1.
Conclusions: Our data indicate that LG micro-fragmented adipose tissue retains either per se, or in its embedded
MSCs content, the capacity to induce vascular stabilization and to inhibit several macrophage functions involved
in inflammation.
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Background
Mesenchymal stromal cells (MSCs) are multipotent
cells present in the stroma of many (if not all) human
organs and tissues. They possess multi-lineage differ-
entiation capacity [31, 32 ] and a potent paracrine ac-
tivity [8, 30], which makes them an attractive tool for
cell-based therapies [8, 28].
Among most of the MSC sources, adipose tissue is
ideal because of the abundance, easy access and the sim-
ple isolation procedures. Indeed, adipose-derived MSCs
(Ad-MSCs) can be easily obtained by a minimal invasive
surgical procedure and expanded in vitro. In addition,
Ad-MSCs have been shown to possess strong regenera-
tive properties when transplanted in vivo in experimen-
tal animal models [11, 24, 33].
However, as for other MSC types, the use of Ad-MSCs
is limited because of the high number of cells required
in most of the clinical protocols in current human trials
[17, 42]. Ad-MSCs are routinely obtained enzymatically
from fat lipoaspirates (LP) as SVF and may undergo pro-
longed ex vivo expansion with significant increased risk
of cell transformation and senescence [41], which leads
to clinical results below the expectations. Besides, these
techniques have complex regulatory issues [36].
For this reason, it is necessary to develop new proce-
dures to obtain Ad-MSCs with minimal manipulation
techniques. To this purpose, prof. Tremolada and col-
leagues [4] recently developed an enzyme free technol-
ogy able to obtain a micro-fragmented fat preparation
named Lipogems® (LG) containing a significant number
of Ad-MSCs. This novel technology reduces the size of
the adipose tissue clusters by means of mild mechanical
forces while eliminating pro-inflammatory oil and blood
residue. The technique is gentle and intra-operatively
provides micro-fragmented fat in a short time (15-20’),
without expansion and/or enzymatic treatment. This
non-expanded micro-fragmented adipose tissue has been
shown to possess regenerative properties, particularly
when injected into inflammatory or ischemic tissues [5].
In the present study, we aimed to establish if LG placed
in culture in a serum free medium retained efficient cells
able to release potential active molecules. In particular,
we investigated the properties of LG and its derived
MSCs (LG-MSCs) population, focusing on their capacity
to affect angiogenesis and inflammation through a para-
crine activity.
Methods
Lipogems processing from adipose tissue
According to the policies approved by the Institutional
Review Boards for Human Studies local ethical commit-
tees (IRB 48/2013, Istituto Neurologico Carlo Besta), all
tissue samples were obtained after signed informed con-
sent (2 male and 3 female, age ranging from 34–64).
Lipogems (LG) was prepared as previously described [4].
Briefly, around 100 ml of adipose tissue was processed
using LG device (provided free of charge for this study
by Lipogems® International Spa). The harvested fat was
then introduced into the Lipogems® processing kit. The
Lipogems® system consists of a disposable kit for the
aspiration, processing and reinjection of autologous adi-
pose tissue. Its core is a disposable and closed device
filled with saline solution that progressively reduces the
size of adipose tissue clusters by means of mild mechan-
ical forces and eliminates pro-inflammatory oil and
blood residues through a minimal manipulation “enzyme
free” technique in a closed and aseptic system completely
prefilled by room temperature physiological solution. The
technique is gentle and intra-operatively provides micro-
fragmented fat in a short time (15-20’), without expansion
and/or enzymatic treatment.
Isolation, expansion and characterization of LG-MSCs
Human LG specimens (about 2 ml for each sample)
were processed for MSC isolation. The LG-MSCs were
isolated following a similar procedure described for fat
specimens [11, 41]. Briefly, sterile LG samples were re-
peatedly washed with PBS (Phosphate buffered saline)
for blood residual by centrifugation at 250 x g. After li-
quid phase removal, collagenase solution (0,25 % w/v)
(SIGMA St. Louis, Mo, USA) plus 200 μl DNAse (Sigma
Aldrich, St. Louis, MO, USA) at 1:100 dilution were
added to LG. All tubes were then incubated overnight at
37 °C. After enzymatic digestion, cells were washed by
centrifugation at 250 x g for 10’. Pellets were re-
suspended in IMDM (Iscove’s Modified Dulbecco’s
Medium) added with 5 % FBS (Fetal Bovine Serum)
(Gibco, Life Technologies, Monza, Italy), seeded into T25
culture flasks, and incubated at 37 °C in a humidified at-
mosphere containing 5 % CO2. Alternatively, an aliquot of
the cell pellet was seeded on chamber slide, and cultured
for 72 h before processing for immunocytochemistry. The
following day, the medium was aspirated and replaced
with IMDM+ 5 % FBS and 50 ng/ml bFGF (LONZA
Walkersville, MD. USA). Upon 5–7 days of culture, the
adherent LG-derived cells were harvested with trypsin and
processed for the removal of CD31+ cells by using mag-
netic beads (Invitrogen, Italy, CELLection™ Pan Mouse
IgG Kit,) as previously described [3]. Briefly, cells were
counted and re-suspended in PBS+ 0.2 % BSA at a con-
centration of 106/ml. Around 5x106 CD31+ pan beads
were added to cells and incubated at 4 °C for 30’ under
gentle rotation. At the end of incubation, the CD31+
cells (i.e. the ECs) bound to magnetic beads were sepa-
rated with a magnetic apparatus, while the remaining
CD31− cells, i.e. LG-MSCs, were expanded in IMDM
+5 % FBS and routinely passed at 70–80 % confluence.
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For this study, cultures were not expanded for more
than 3–5 in vitro passages.
Flow cytometry (FC) was used to confirm LG-MSC mes-
enchymal phenotype at passages 3. Briefly, after trypsiniza-
tion, cells were re-suspended in PBS at a concentration of
1x105 /100 μl and incubated with 10 μl of conjugated pri-
mary antibody for 30’ at 4 °C in the dark. Phycoerythrin
(PE) conjugate-antibodies were used: anti-human CD90PE
(Millipore, Billerica, MA, USA; working dilution 1:10),
anti-human CD105PE, anti-human CD73PE, anti-human
CD44PE (BD Pharmingen™, San Jose, CA, USA; working
dilution 1:10). Aspecific staining was determined with ap-
propriate Isotype Control. At least 20,000 events were ac-
quired for each sample on a FACS Advantage SE (BD
Bioscience, San Diego, CA, USA) flow cytometer and the
acquisition analyses were performed using a CellQuest
software (BD Bioscience, San Diego, CA, USA).
Preparation of conditioned medium (CM) from LG
(LG-CM) and LG-MSCs (LG-MSC-CM)
Two different procedures for preparation of LG-CM and
LG-MSCs-CM have been used because of the consistent
secretions of growth factors and cytokines for Luminex
analysis. Briefly, freshly LG was washed in PBS at least
three time by centrifugation at 250 g for 10’. LG was
then aspirated and seeded (around 2 ml) in T25 flask in
5 ml of IMDM serum free medium (a similar amount of
LG was used for cells extraction with collagenase). The
flasks (five for each LG preparation) were incubated for
5 days at 37 °C in 5 % CO2. At the end of the incuba-
tion, medium was aspirated and centrifuged at 250 x g
for 10’. LG-CM was filtered 0.22 μ, aliquoted and stored
at −20 °C until use. LG-MSCs-CM was prepared upon
harvesting LG-MSCs from culture at passages 3 starting
from CD31+ selection that eliminate ECs from primary
culture. Around 2x105 LG-MSCs were seeded in 5 ml of
IMDM+ 5 % FCS and incubated at 37 °C for 3 days. At
the end of the incubation, LG-MSCs-CM was centri-
fuged, filtered, and stored at −20 °C until used.
Histology and Immunohistochemistry
LG and LP samples from 5 patients were fixed in 10 % for-
malin (Bio-Optica, Milan, Italy), embedded in paraffin
(Bio-Optica, Milan, Italy) and then processed for histology
and immunohistochemistry. Hematoxylin and eosin
(Bio-Optica, Milan, Italy) stained serial sections of five
micrometer thickness were immunostained for the de-
tection of proteins of interest according to standard
protocols [15]. Briefly, the sections were transferred to
glass slides coated with poly-lysine, deparaffinized in
100 % xylene, and rehydrated in graded ethanol. All
samples were then processed by the avidine-biotin per-
oxidase complex method according to manufacturer’s
recommendations (DakoCytomation, Carpenteria CA,
USA, LASB kit). The antibodies used for immunohisto-
chemistry on LP and LG and immunocytochemistry on
cells isolated from LG enzymatic digestion and cultured
for 40–72 h and from LG-derived MSCs were: anti-
NG2 (SANTA CRUZ, Biotechnology, California USA,
working dilution 1:50), anti-CD146 (LEICA Biosystem
Nussloch Germany, working dilution 1:50), anti-smooth
muscle actin (SMA) (BIO-OPTICA Milan, Italy, working
dilution 1:1000), anti-CD31 (LEICA Biosystem Nussloch
2015 Germany, working dilution 1:50), anti- vascular endo-
thelial growth factor (VEGF) (BIO-OPTICA, Milan, Italy,
working dilution 1:100), anti-CD105 (MONOSAN,
Uden The Netherlands, working dilution 1:50), anti-
CD34 (LEICA, Biosystem Nussloch Germany, working
dilution 1:200), anti-CD44 (DAKO Glostrup, Denmark,
working dilution 1:50), anti-transforming growth factor
β1 (TGFβ1) (SANTA CRUZ Biotecnology, California,
USA, working dilution 1:200).
Evaluation of the angiogenic potential of LG and LG-MSCs
To assess the angiogenic potential of LG and LG-MSCs,
we investigated the activity of their conditioned medium
(CM) on Human Umbilical Vein Endothelial Cells
(HUVECs) (LONZA Walkersville, MD. USA). HUVECs
were routinely maintained in EGM bullet kit (LONZA
Walkersville, MD. USA) plus 10 % FBS. HUVEC prolif-
eration assay was performed as previously described [1].
Briefly, HUVECs were harvested from culture flasks by
trypsin. After enzyme inactivation and centrifugation,
cells were re-suspended in EGM basal medium + 0.2 %
BSA and counted. To evaluate the growth response to
LG-CM and LG-MSCs-CM, 5x104/ml HUVECs were
seeded into a 24-multiwell plate (Corning, NY, USA)
coated with collagen type I. After adhesion, medium was
aspirated and replaced with EGM complete medium +
10 % FBS supplemented or not with different dilutions
of LG-CM and LG-MSCs-CM. Positive control growth
medium consisted in EGM Bullet kit complete medium.
After 72 h, cells were washed, fixed and stained. Cells
were counted in triplicate with a calibrated ocular eye-
piece in 10 different fields (40x magnification). To test
the effect of LG-CM and LG-MSCs-CM on HUVEC
tube formation, we used growth factor reduced-matrigel
assay (Sigma) as described by Kleinman et al. [19].
Briefly, around 50 μl of matrigel was placed into cold
(4 °C) 96-multiwell plate (Corning, NY, USA) at 37 °C
for 30’ until jellification. HUVECs were then seeded on
matrigel at a concentration of 104 cells/well in 50 μl of
EGM basal medium diluted (from 1:1 to 1:8) or not with
LG-CM and LG-MSCs-CM. At day 1 and 5, the number
of HUVEC tube formations were counted with an
inverted microscope (10x magnification) and reported as
n° of tube structures/field. To evaluate the content of
angiogenic factors in both LG-CM and LG-MSCs-CM,
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Luminex analysis was performed (Labospace, Milan,
Italy). Samples were analyzed according to the manufac-
turer’s protocol. AM expression on HUVECs was ana-
lysed by flow cytometry (FC) after exposure to LG-CM
and LG-MSCs-CM at various dilutions (from 1:1 to 1:8).
Briefly, HUVECs were washed and incubated for 24 h with
LG-CM or LG-MSCs-CM. Cells were then washed, trypsi-
nized, re-supsended in PBS, and processed for FC analysis
as described above. Anti-CD106/VCAM-1-phycoerythrin
(Serotech, Italy) and anti-CD54/ICAM-1- fluorescein
isothiocynate (Immunotech, Milan, Italy) antibodies
were used.
Evaluation of anti-inflammatory activity of LG and
LG-MSCs
The anti-inflammatory activity of LG and LG-MSCs was
tested by treating the U937 monocyte cell line (ATCC
Manassas VA, USA) with LG-CM and LG-MSCs-CM.
Cells were routinely maintained in RPMI + 10 % FBS
and passed twice a week. Corning Costar Transwell
5 μm pore size supports (Celbio, Milan, Italy) were used
to test the effects of LG-CM and LG-MSCs-CM on
U937 migration. MCP-1 chemokine (Sigma Aldrich, St.
Louis, MO, USA) was used as positive chemotactic fac-
tor. For each test, 106 cells in 200 μl of IMDM +0.2 %
BSA were routinely placed at the top of the membrane
insert (the upper compartment of the well). To evaluate
spontaneous migration, 500 μl of control IMDM+ 0.2 %
BSA medium were added to the lower compartment of
the wells. To evaluate LG-CM and LG-MSCs-CM activ-
ity, different dilutions (from 1:1 to 1:8) were added in
the lower compartment of each well in the presence or
in the absence of MCP-1 (10 ng/ml). Migration assay
was carried out for 6 h at 37 °C in 5 % CO2 [3]. The
membrane inserts were then removed, fixed in 10 % for-
malin and stained with Wright’s solution (Sigma Aldrich,
St. Louis, MO, USA). Cells attached to the upper surface
of the filter were removed with a swab and cells mi-
grated across the membrane were counted by examining
the lower surface with a microscope. Data are reported
as the total number of cells found in 10 different fields
for each membrane at 40x magnification. Each deter-
mination was performed in duplicate. Since interaction
of inflammatory cells to endothelium is an important
step in inflammation [29], adhesion of U937 to HUVECs
was performed following a previously described proced-
ure [31]. Briefly, HUVECs were seeded onto collagen-
coated 24-multiwell plates (Corning, NY, USA) at a
concentration of 5x104/500 μl in complete endothelial
basal medium EGM Bullet kit. The plates were incu-
bated for 4 to 5 days to obtain a cell monolayer.
HUVECs were activated by adding tumor necrosis fac-
tor-alpha (TNFα; 25 ng/ml; Sigma Aldrich) for 12 h.
HUVECs were then washed with PBS and allowed to
interact with U937 (105 cells/well) for 30’ in RPMI-
1640 (EuroClone Milano, Italy) containing 0.2 % BSA
(control). Alternatively, U937 were primed for 12 h
with different dilutions (from 1:1 to 1:8) of LG-CM and
LG-MSCs-CM and then seeded on HUVECs (test con-
ditions). The unbound U937 were removed by three
washes with warm PBS and U937 attached to HUVECs
were fixed for 5’ with 100 μl of cold methanol and stained
with Diff Quick (Merz-Dade, Dudingen, Switzerland) for
30’ at room temperature. The plates were then washed
several times with deionized water and the U937 bound to
HUVECs were counted with a calibrated eyepiece in 15
different fields (40× magnification). Each test was per-
formed in quadruplicate. ELISA-kits were used to quantify
the production of RANTES and MCP-1 (R&D Systems,
UK) by U937 under basal culture conditions, in the pres-
ence of Lipopolysaccharide (LPS) inflammatory stimuli
(1ug/ml, Sigma) combined or not with different dilutions
of LG-MSCs-CM and LG-CM. All the data were normal-
ized for 106 cells in 24 h incubation subtracting the basal
level of the same chemokines present in the LG-MSCs-
CM and in LG-CM used.
Statistical analysis
Statistical analysis was performed with the Statistical Pack-
age for Social Science (SPSS version 13, IBM, Armonk, NY,
USA). Statistical differences were evaluated by the analysis
of variance followed by Tukey-Kramer multiple compari-
son test and by the two-tailed, unpaired Student’s t-test.
P ≤ 0.05 was considered statistically significant as indicated
in the figures.
Results
LG and LG-MSC characterization
H&E staining and immunohistochemical analysis (Fig. 1)
revealed that LG has a very high content of microvessels,
compared to LP (Fig. 1a, b). Indeed, CD31+ cells are 10
times more in LG than in LP (Fig. 1c, d). SMA staining
indicated that LP contains more larger vessels than LG
(Fig. 1e, f ). The analysis of NG2, a marker specifically
expressed on pericytes but not on mECs [16], revealed
that the number of pericytes, which are only present on
microvessels [18], is higher in LG compared to LP
(Fig. 1g, h). In contrast, CD146 seemed higher in LP,
while in LG is more localized within the microvessels
(Fig. 1i, j). The angiogenic factor VEGF is present in the
connective of both LG and LP, despite LG showed less
connective matrix than LP (Fig. 1k, l).
To further investigate the cell content in LG speci-
mens, collagenase treatment was performed. Upon en-
zymatic digestion of LG, several aggregates or cell
clusters with capillary-like structures were observed
(Fig. 2), as detected by light microscopy. Upon 48–72 h
of culture, cell aggregates gave rise to colonies with
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Fig. 1 Histological and immunohistochemical analysis of LG and LP. H&E staining shows higher content of microvessels in LG (a) compared to LP
(b). The immunohistochemistry shows an intense staining (black arrows) for the endothelial marker CD31 (c and d) and mural cell marker SMA
(e and f). Staining with NG2 (g and h) was associated to microvessels and showed the presence of pericytes, that were more abundant in LG
compared to LP (black arrows). Staining for CD146 (i and j), a marker present on both pericytes and endothelial cells, was more diffuse and intense in
LP, while in LG was more associated to microvessels (black arrows). VEGF staining was present in the connective of both LG (k) and LP (l); LG showed
less connective matrix than LP (Magnification 20x)
Fig. 2 Cultures of LG-MSCs upon collagenase dissociation. Representative of five different Lipogems®-derived MSCs (LG-MSC) cultured from 1 h (a)
to 21 days (f). Upon enzymatic digestion of human LG specimens, the obtained clusters were seeded in IMDM + 5 % FBS (a) in order to allow the
adhesion and the proliferation of the released cells. After 72 h (b) all cultures showed the capacity to adhere on a plastic substrate and the
typical stromal morphology. Starting from 5 days of culture (c) clusters of endothelial cells (black arrow) were highly distinguishable among the
stromal cells and after 10 days (d) were removed from the culture by using CD31+ magnetic beads. Stromal and endothelial cell population was
cultured separately and at 21 days reached complete confluence (e) and (f) respectively. (Magnification 10x)
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endothelial-like morphology, surrounded by fibroblastic
shape cells. During culture expansion, these fibroblastic
shaped cells increased their number more rapidly than
endothelial-like cells and, very often, grew above the
endothelial-like colonies. By using magnetic beads coated
with CD31, it was possible to separate the two different
populations, one positive for CD31, with endothelial
appearance, and, the second negative for CD31, with
fibroblastic-like morphology (all data are summarized
in Fig. 2). The immunostaining of early LG cell cultures
(48-72 h) with endothelial, pericyte and mesenchymal
markers indicated the presence of a significant number
of cells positive for CD31, CD34 and CD146 (Fig. 3).
Several cells were positive for NG2 CD44, CD105 and
SMA. In addition, most of the cells were strongly posi-
tive for TGFβ1 and VEGF, usually secreted by MSCs.
Interestingly, secondary cultures of LG-derived cells
(2–3 in vitro passages), became negative for CD31, CD34
and KDR (a receptor for VEGF); CD146 was strongly re-
duced, whereas several mesenchymal and pericyte markers
(CD105, CD44, SMA and NG2), as well as specific mesen-
chymal growth factors (TGFβ1 and VEGF) were main-
tained (Fig. 4). In summary, the immunostaining of early
culture of LG-derived cells revealed the presence of two
different populations: mECs and pericyte-associated MSCs.
However, upon only 2–3 in vitro passages, cells with
endothelial phenotype were lost and only cells with
mesenchymal and pericyte features remained. The MSC
phenotype of LG-MSCs cultures was also confirmed by
FC analysis (cells were positive for CD90, CD73 and
CD105 [12] - Fig. 5).
LG and LG-MSC angiogenic properties
It has been shown that LG-MSCs naturally express a set
of vasculogenic genes and that LG, when transplanted
into an experimental ischemic tissue, improved tissue re-
pair possibly by stimulating angiogenesis [4, 5]. In order
to broaden our knowledge, we here investigated whether
LG and LG-MSCs were able to release molecules affect-
ing angiogenesis. Collagenase digestion of LG was neces-
sary to obtain a sufficient number of cells and to
develop a culture in few days. Indeed, the mechanical
dissociation, as well as the direct cultivation, required up
to 3–4 weeks. The LG-CM and LG-MSCs-CM were
then tested on HUVECs to evaluate proliferation, cord-
like formation and ICAM-1 and VCAM-1 expression
(Fig. 6). Under our experimental conditions, the addition
of different dilutions of both LG-CM and LG-MSCs-CM
improved only slightly HUVEC proliferation (Fig. 6a),
but increased capillary-like tube formation after 12 h
Fig. 3 Immunostaining of early culture of cells obtained after collagenase digestion of LG. Endothelial, pericyte and mesenchymal markers were used
to characterize the cells extracted from LG. Cells analyzed upon 48-72 h of culture, showed the presence of a significant number of cell colonies
positive for CD31, CD34 endothelial markers, surrounded by fibroblastic negative cells (black arrows). Conversely, several fibroblastic-like cells were
positive for the pericyte marker NG2, and the mesenchymal markers CD105, CD44 and SMA. Interestingly, CD146 stained very intensely both
colonies and fibroblastic cells; very few cells were negative. Fibroblastic-like cells were also positive for TGFβ1 and VEGF, growth factors that
are usually secreted by MSCs. (Magnification 20x)
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incubation (Fig. 6b) compared to control medium condi-
tion. However, at 24 h HUVEC cords spontaneously
regressed under control medium condition, whereas in
the presence of LG-CM a significant number of cords
were still present. LG-MSCs-CM was less effective
(Fig. 6c). These data suggest a higher capability of LG-
CM in stabilizing neoformed vascular-like structures
compared to their LG-MSCs counterpart.
It is well known that Angiopoietins (Ang-1 and Ang-2)
are involved in vascular maturation [13]. Thus, we exam-
ined, together with a panel of other angiogenic-related
molecules, LG and LG-MSCs secretome. Although the
different procedures adopted to obtain LG-CM and LG-
MSCs-CM cannot allow an absolute comparison, the
Luminex assay seemed to indicate that LG secreted less
VEGF and MMP-2, but a significant higher amount of
Ang-1 and Ang-2 as well MMP-7 and MMP-9 com-
pared to LG-MSCs (Fig. 6d). We next examined the
capacity of LG-CM and LG-MSCs-CM to modulate
HUVEC expression of ICAM-1 and VCAM-1. Different
dilutions of LG-CM and LG-MSCs-CM were added to
HUVECs cultured in the absence or in the presence of
TNFα, an inflammatory cytokine (IC) able to enhance
AM expression [26]. At 50 % dilution, the addition of
either LG-CM or LG-MSCs-CM significantly reduced
the expression of ICAM-1, both the base line as well as
the increment induced by TNFα (Fig. 6e). VCAM-1 ex-
pression was significantly reduced by LG-CM; a similar
trend was observed by adding LG-MSCs-CM only in
the presence of TNFα (Fig. 6f ).
LG and LG-MSC anti-inflammatory properties
It has been reported that MSCs are the guardians of in-
flammation [34, 37] and their injection ameliorates
clinical signs in animals with induced inflammatory dis-
eases [22]. We here investigated whether LG or LG-
MSCs possess anti-inflammatory properties, in particu-
lar affecting some macrophage functions involved in in-
flammation (Fig. 7). U937, a human monocyte cell line,
were used to investigate macrophage functions. We
first examined the capability of LG-CM and LG-MSCs-
CM of affecting U937 migration. Our results indicate
that the presence of LG-CM and LG-MSCs-CM re-
duced U937 motility in a dose dependent manner
Fig. 4 Immunocytochemistry of secondary culture of LG-derived MSCs. Immunocytochemistry was performed on LG-MSCs after 2–3 in vitro passages.
Under these experimental conditions, LG-MSCs lost the expression of endothelial markers CD31, CD34 and KDR (a receptor for VEGF), while
retaining pericyte and mesenchymal markers NG2, CD105 and SMA. Cells were still positive for TGFβ1 and VEGF. To note, CD146 positive cells
(black arrow) were very few, suggesting that this marker in LG was probably mostly expressed by the cells of endothelial origin (Magnification 20x)
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(Fig. 7a). The inhibitory effect of LG-CM and LG-
MSCs-CM on U937 was more evident when the migra-
tion test was performed in the presence of MCP-1/
CCL-2, a chemokine shown to recruit inflammatory
cells to the site of inflammation [40]. Under this experi-
mental condition, both LG-CM LG-MSCs-CM were ef-
fective, particularly at higher dilutions (Fig. 7a).
Because the adhesion of inflammatory cells on the vas-
cular endothelium is a hallmark of the inflammatory
process [20], we next analyzed whether LG-CM and
LG-MSCs-CM affect U937 adhesion on a HUVEC
monolayer in the absence or in the presence of TNFα,
an inflammatory cytokine known to enhance the sticki-
ness of inflammatory cells on the endothelium [26].
The addition of LG-CM (1:2 and 1:4 dilutions) signifi-
cantly inhibited U937 adhesion both in the absence and in
presence of TNFα. LG-MSCs-CM, reduced the adhesion
on HUVECs only following TNFα stimulation (Fig. 7b).
Finally, we analyzed the ability of U937 to secrete
RANTES and MCP-1, two chemokines involved in in-
flammation [25]. The incubation of U937 with LG-CM
and LG-MSCs-CM at 1:2 dilution significantly inhibited
RANTES secretion both under basal condition and upon
stimulation with LPS (Fig. 7c). Similar results were ob-
tained for MCP-1 (Fig. 7d).
Discussion
Because of their strong functional and phenotypic simi-
larities with bone marrow MSCs [21] and their easy iso-
lation through a minimally invasive surgery, Ad-MSCs
are considered an attractive biological tool for advanced
cell therapies in humans [8]. In general, the clinical use
of MSCs is strongly limited because of the significant
manipulations required during isolation procedures and
in vitro expansion, thus falling under the highly demand-
ing requirements imposed by cGMP guidelines. To over-
come this problem, new approaches using minimal
manipulation on human cells, tissues and tissue-based
products have been developed. Recently, prof. Tremo-
lada and colleagues developed and patented an innova-
tive technique to process fat specimens, such as LP,
without the use of enzymes, to obtain an autologous
micro-fragmented adipose tissue product ready to be
injected into patients or eventually cryopreserved for
future applications [4]. Application of LG in humans
[35, 38, 39] as well as in experimental animal ischemic
Fig. 5 Characterization of Lipogems®-derived MSCs. The levels of CD44-PE, CD73-PE, CD90-PE, CD105-PE, CD31-PE markers in LG-MSCs were analyzed by
flow cytometry. The percentage indicate the positivity of the cells for their relative surface markers, while the gate indicate the isotypic control
(Magnification 10x)
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disease models have shown some beneficial effects pos-
sibly mediated by the capability of LG to release vasculo-
genic/angiogenic molecules [5]. In an attempt to better
understand the functional properties of LG, we here in-
vestigated its angiogenic and anti-inflammatory features
in vitro. To this end, fresh LG preparations were cul-
tured in serum free condition to better analyze their se-
creted factors. In parallel, from the same amount of LG
we extracted and cultured LG-MSCs to determine if a
similar functional activity was retained. Comparative
activity between LG and their isolated cellular content
i.e. LG-MSCs was not the object of this study because of
the impossibility to estimate the number of cells present
in LG preparations and the different culture conditions.
At the histological level, LG is very rich in microves-
sels and this was confirmed by the intense positivity of
LG specimens for CD31 and SMA (endothelial and
mural cell markers). In addition, the wall of the micro-
vessels in LG was also positive for CD146 which is con-
sidered a pericyte marker, but it is also known to be
expressed on ECs particularly under inflammatory con-
ditions [2].
Differently from other previous studies that investi-
gated the expression of CD146 and CD34 as pericyte
and mEC markers respectively [4], we here analyzed the
expression of NG2 as univocal marker for pericytes [27].
We found that NG2 positive cells were significantly
present in LG microvessel, and the results were also
Fig. 6 Angiogenic properties of LG and LG-MSCs. The angiogenic properties of LG and LG-MSCs were investigated by testing their CM. In (a) the
effect of LG-CM and LG-MSCs-CM on HUVECs proliferation. EGM medium was used as positive control for proliferation, EGM medium without
growth factors the negative control (CTRL) (* p < 0.05; ** p < 0.01 versus CTRL). In (b) the quantification of cord formations on MTG by HUVECs
under the influence of LG-CM and LG-MSCs-CM at 12 h and at 24 h in (c) (* p < 0.05; ** p < 0.01 versus CTRL). In (d) the analysis of angiogenic
molecules present in the secretome of LG-CM in comparison to LG-MSCs-CM. MMP2 was significantly reduced in LG-CM, while ANG-1 and
ANG-2 were increased (* p < 0.05; ** p < 0.01 versus LG-MSCs-CM). In (e) and in (f) the effect of LG-CM and LG-MSCs-CM on the expression of
HUVEC ICAM-1 and VCAM-1 respectively (* p < 0.05; ** p < 0.01 versus CTRL; °p < 0.05, °° p < 0.01 versus TNFα treatment)
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confirmed by the immunocytochemical analysis of the
freshly isolated cells derived from LG upon collagenase
digestion. Differently from other published results [4, 9],
the use of the enzyme was necessary to obtain a suffi-
cient number of cells in 7–14 days, while generally 4–6
weeks are required for a direct place of LG in culture
medium or a mechanical dissociation using a Pasteur
pipette. Substantially, we observed that LG was com-
posed by an abundant number of mECs islets (positive
for CD31, CD34 and CD146) surrounded by several stro-
mal cells expressing the typical mesenchymal markers
(CD44, CD105, TGFβ1), most of them positive for NG2.
In summary, our results broaden previous data showing,
for the first time, that most of LG-MSCs are of pericyte
origin and positive for NG2. Because the pericytes within
the microvessels have been proposed to be the real im-
mature precursors of all different tissue-derived MSCs
[7, 10], we can conclude that immature MSC progeni-
tors are highly concentrated in LG. This conclusion is
also supported by the analysis of the secondary culture
of LG-MSCs, where, besides a high positivity for the
typical MSCs markers CD90, CD105, CD73 [12] most
of the cells were also positive for NG2 (almost 100 %).
Interestingly, CD146 was significantly reduced in the
secondary culture, whereas mECs were almost absent.
Thus, at least within the adipose tissue, CD146 stains
mostly cells of endothelial origin rather than pericytes.
The analysis of LG angiogenic activity demonstrated
that it stimulates only marginally HUVEC proliferation,
whereas it significantly reduces AM expression (ICAM-1
and VCAM-1) and improves cord-like formations, indi-
cating a preferential ability of LG-CM to favor vascular
stability and maturation. This result was partially con-
firmed by the analysis of its secretome that indicated a
Fig. 7 LG-CM and LG-MSCs possess anti-inflammatory properties. The capacity of LG-CM and LG-MSCs to affect inflammatory cell functions
was tested on the U937 monocyte cell line. In (a) the effect of LG-CM and LG-MSCs-CM on U937 migration. Different dilutions of LG-CM and
LG-MSCs-CM were placed in the lower compartment of a transwell insert (5um pore size). The chemokine MCP-1 at (10 ng/ml) was used as a
positive stimuli for U937 migration. RPMI+ 0.2 % BSA was the control medium (CTRL) (* p< 0.05; ** p< 0.01 versus CTRL; °p< 0.05, versus MCP-1 treatment).
In (b) adhesion of U937 to HUVECs monolayer in the presence of LG-CM and LG-MSCs-CM. TNFα at 20 ng/ml was used to activate HUVECs
(* p < 0.05; ** p < 0.01 versus CTRL; °p < 0.05, °° p < 0.01 versus TNFα treatment). The photos below the figure show the morphological
appearance of U937 attached to HUVECs primed with TNFα, LG-CM and LG-MSCs-CM after 30’ incubation (5x magnifications). In (c) and in (d) the
release of RANTES and MCP-1 by U937 under the influence of LG-CM and LG-MSCs-CM stimulated or not with LPS (1ug/ml) respectively
(*p < 0.05; **p < 0.01 versus CTRL; °p < 0.05, °° p < 0.01 versus LPS treatment)
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high content of both Ang-1 and Ang-2, and low levels of
VEGF and MMP2 compared to LG-MSCs-CM that, in
this context, had an effect on HUVECs but with an ap-
parent lower efficacy compared to LG-CM, although a
comparative analysis between the two CMs cannot be
done. In line with our previous observation on Ad-MSCs
isolated through enzymatic digestion [6], both LG-CM
and LG-MSCs-CM did not contain inflammatory cyto-
kines. We also found for the first time that both LG-CM
and LG-MSCs-CM have potent anti-inflammatory proper-
ties. Indeed, they both reduced migration, adhesion to an
activated EC monolayer and release of RANTES and
MCP-1 chemokines of U937, monocytes of tumorigenic
origin [23] used as a valid model to investigate the inflam-
matory properties of monocytes [23, 36]. Taken together
our results clearly indicate that LG and its purified MSCs
content are able to block several important monocyte in-
flammatory functions.
Conclusion
Our results point at LG as a valid micro-fragmented fat
derivative that retains anti-inflammatory and vascular
stability properties even higher than its purified and cul-
tured Ad-MSC content. Because of the minimal manipu-
lation, LG bypasses the complex requirements of GMPc
guidelines, with a dramatic reduction of the costs for
cell-based therapies on human patients. The major limi-
tation is represented by the technical difficulties in the
estimation of the real cell content and, in particular, the
number of MSCs/ml of LG. In addition, the impossibility
at this moment of being inoculated in patients through
the systemic route (intravenous injection) limits its clin-
ical use at a local treatment. Finally, because LG has an
impressive secretory activity, its CM may be used not
only for the identification of active molecules involved in
angiogenesis or inflammatory processes, but also to pro-
duce microvescicles [14] that might be used for alterna-
tive therapies of inflammatory diseases in human.
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